- Home
- AVIR vs EARN Comparison
AVIR vs EARN Comparison
Compare AVIR & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- EARN
- Stock Information
- Founded
- AVIR 2012
- EARN 2012
- Country
- AVIR United States
- EARN United States
- Employees
- AVIR N/A
- EARN N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- EARN Real Estate Investment Trusts
- Sector
- AVIR Health Care
- EARN Real Estate
- Exchange
- AVIR Nasdaq
- EARN Nasdaq
- Market Cap
- AVIR 273.0M
- EARN 223.5M
- IPO Year
- AVIR 2020
- EARN 2013
- Fundamental
- Price
- AVIR $3.90
- EARN $5.93
- Analyst Decision
- AVIR Hold
- EARN Buy
- Analyst Count
- AVIR 1
- EARN 2
- Target Price
- AVIR $6.00
- EARN $6.13
- AVG Volume (30 Days)
- AVIR 426.9K
- EARN 282.4K
- Earning Date
- AVIR 08-06-2025
- EARN 08-11-2025
- Dividend Yield
- AVIR N/A
- EARN 16.22%
- EPS Growth
- AVIR N/A
- EARN N/A
- EPS
- AVIR N/A
- EARN N/A
- Revenue
- AVIR N/A
- EARN $35,893,000.00
- Revenue This Year
- AVIR N/A
- EARN $3.72
- Revenue Next Year
- AVIR N/A
- EARN $18.60
- P/E Ratio
- AVIR N/A
- EARN N/A
- Revenue Growth
- AVIR N/A
- EARN 43.30
- 52 Week Low
- AVIR $2.46
- EARN $4.33
- 52 Week High
- AVIR $4.15
- EARN $7.14
- Technical
- Relative Strength Index (RSI)
- AVIR 67.66
- EARN 55.19
- Support Level
- AVIR $3.36
- EARN $5.85
- Resistance Level
- AVIR $3.53
- EARN $6.05
- Average True Range (ATR)
- AVIR 0.15
- EARN 0.09
- MACD
- AVIR -0.00
- EARN -0.00
- Stochastic Oscillator
- AVIR 97.24
- EARN 54.55
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics, and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.